A Case of Carcinoid Tumor-Associated Hypercalcemia

Abstract

Hypercalcemia as a complication of carcinoid tumors is extremely rare. Accordingly, we report the case of a 55-year-old male with metastatic carcinoid tumor and hypercalcemia, which corrected when the patient was treated with octreotide for symptomatic relief of watery diarrhea. The etiology of the hypercalcemia is presumed to be a neoplastic expression of fibroblast growth factor-23, which was found to be inappropriately high-to-normal when other factors such as parathyroid hormone, calcitonin and vitamin D were appropriately low or low-to-normal.

Metabolic bone disease in the context of metastatic neuroendocrine tumor: differentiation from skeletal metastasis, the molecular PET-CT imaging features, and exploring the possible etiopathologies including parathyroid adenoma (MEN1) and paraneoplastic humoral hypercalcemia of malignancy due to PTHrp hypersecretion

“…HHM in cases of NET has also been reported. It has been reported in cases of pheochromocytoma [10] and carcinoid, [11] but are most commonly seen in cases of pancreatic NET. [12] A case III patient was labeled to have HHM from the pancreatic primary and thus was proven to have metabolic bone disease rather than skeletal metastasis.…”